Liebe Besucherinnen und Besucher,
heute ab 15 Uhr feiern wir unser Sommerfest und sind daher nicht erreichbar. Ab morgen sind wir wieder wie gewohnt für Sie da. Wir bitten um Ihr Verständnis – Ihr Team von Sack Fachmedien
E-Book, Englisch, 256 Seiten, E-Book
Han / Davis / Wang Evaluation of Drug Candidates for Preclinical Development
1. Auflage 2010
ISBN: 978-0-470-57488-1
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
Pharmacokinetics, Metabolism, Pharmaceutics, and Toxicology
E-Book, Englisch, 256 Seiten, E-Book
Reihe: Wiley Series in Drug Discovery and Development
ISBN: 978-0-470-57488-1
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
Emphasizes the integration of major areas of drug discovery andtheir importance in candidate evaluation
It is believed that selecting the "right" drug candidate fordevelopment is the key to success. In the last decade,pharmaceutical R&D departments have integrated pharmacokineticsand drug metabolism, pharmaceutics, and toxicology into early drugdiscovery to improve the assessment of potential drug compounds.Now, Evaluation of Drug Candidates for Preclinical Developmentprovides a complete view and understanding of whyabsorption-distribution-metabolism-excretion-toxicology (ADMET)plays a pivotal role in drug discovery and development.
Encompassing the three major interrelated areas in whichoptimization and evaluation of drug developability is mostcritical--pharmacokinetics and drug metabolism, pharmaceutics,and safety assessment--this unique resource encouragesintegrated thinking in drug discovery. The contributors to thisvolume:
* Cover drug transporters, cytochrome P-450 and drug-druginteractions, plasma protein binding, stability, drug formulation,preclinical safety assessment, toxicology, and toxicokinetics
* Address developability issues that challenge pharma companies,moving beyond isolated experimental results
* Reveal connections between the key scientific areas that arecritical for successful drug discovery and development
* Inspire forward-thinking strategies and decision-makingprocesses in preclinical evaluation to maximize the potential ofdrug candidates to progress through development efficiently andmeet the increasing demands of the marketplace
Evaluation of Drug Candidates for Preclinical Development servesas an introductory reference for those new to the pharmaceuticalindustry and drug discovery in particular. It is especially wellsuited for scientists and management teams in small- to mid-sizedpharmaceutical companies, as well as academic researchers andgraduate students concerned with the practical aspects related tothe evaluation of drug developability.
Autoren/Hrsg.
Weitere Infos & Material
PREFACE.
CONTRIBUTORS.
1. INTRODUCTION (Charles B. Davis).
2. PHARMACOKINETICS IN PRECLINICAL DRUG DEVELOPMENT: ANOVERVIEW (Dion Brocks).
3. THE ROLE OF MEMBRANE TRANSPORTERS IN DRUG DISPOSITION(Fanfan Zhou, Peng Duan, and Guofeng You).
4. CYTOCHROME P450: STRUCTURE, FUNCTION, AND APPLICATION INDRUG DISCOVERY AND DEVELOPMENT (Ramesh B. Bambal and StephenE. Clarke).
5. THE ROLE OF DRUG METABOLISM AND METABOLITE IDENTIFICATIONIN DRUG DISCOVERY (Xiangming Guan).
6. PROTEIN BINDING IN DRUG DISCOVERY AND DEVELOPMENT(Vikram Ramanathan and Nimish Vachharajani).
7. PREDICTION OF THE PHARMACOKINETICS IN HUMANS (ChaoHan and Ramesh Bambal).
8. PHARMACEUTICS DEVELOPABILITY ASSESSMENT (LianHuang, Jinquan Dong, and Shyam Karki).
9. SAFETY ASSESSMENT IN DRUG DISCOVERY (Vito G.Sasseville, William R. Foster, and Bruce D. Car).
10. ASSESSMENT OF STRATEGIES UTILIZED TO MINIMIZE THEPOTENTIAL FOR INDUCTION OF ACQUIRED LONG QT SYNDROME AND TORSADE DEPOINTES (Khuram W. Chaudhary and Barry S. Brown).
INDEX.